Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Assets (2018 - 2025)

China SXT Pharmaceuticals has reported Current Assets over the past 8 years, most recently at $26.0 million for Q3 2025.

  • For Q3 2025, Current Assets rose 18.44% year-over-year to $26.0 million; the TTM value through Sep 2025 reached $26.0 million, up 18.44%, while the annual FY2025 figure was $21.3 million, 49.62% up from the prior year.
  • Current Assets for Q3 2025 was $26.0 million at China SXT Pharmaceuticals, up from $21.3 million in the prior quarter.
  • Over five years, Current Assets peaked at $26.0 million in Q3 2025 and troughed at $11.7 million in Q3 2021.
  • A 5-year average of $18.6 million and a median of $20.4 million in 2023 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: plummeted 47.14% in 2021 and later skyrocketed 62.93% in 2024.
  • Year by year, Current Assets stood at $11.7 million in 2021, then grew by 5.99% to $12.4 million in 2022, then rose by 9.19% to $13.5 million in 2023, then skyrocketed by 62.93% to $22.0 million in 2024, then rose by 18.44% to $26.0 million in 2025.
  • Business Quant data shows Current Assets for SXTC at $26.0 million in Q3 2025, $21.3 million in Q1 2025, and $22.0 million in Q3 2024.